Chewable medicine tablet for treating child allergic rhinitis

A technology for allergic rhinitis and chewable tablets, which is applied in the field of pharmaceutical preparations, can solve problems such as general taste masking effect, and achieve the effect of improving stability

Inactive Publication Date: 2015-12-09
JIANGSU ALPHA PHARM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Loratadine has a slightly bitter taste, and it is necessary to add flavoring agents and essences when it is made into dosage forms for children, such as syrup, but the taste-masking effect is general

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] 1) Preparation of Montelukast Sodium Microcapsules

[0028] Eudragil L100 40g

[0029] Octadecanol 2.5g

[0030] PEG60005g

[0031] Montelukast Sodium 10g

[0032] Measure an appropriate amount of 95% ethanol solution, weigh Eudragil L100 according to the prescription ratio, stir and dissolve, dissolve the pulverized montelukast sodium powder in the above solution, add stearyl alcohol and PEG6000, and spray at a feed rate of 10ml / min , the atomization pressure is 0.3Mpa, the air inlet temperature is 90-130°C, and the air outlet temperature is 60-80°C. Montelukast sodium microcapsules are prepared, and the encapsulation efficiency is >85%.

[0033] 2) Preparation of loratadine microcapsules

[0034] Eudragil S100 40g

[0035] Glyceryl monostearate 3g

[0036] PEG60005g

[0037] Loratadine 20g.

[0038] Measure an appropriate amount of 95% ethanol solution, weigh Eudragil L100 according to the prescription ratio, stir and dissolve, dissolve the pulverized loratadi...

Embodiment 2

[0045] Preparation of Montelukast Sodium and Loratadine Microcapsules

[0046] Eudragil L100 60g

[0047] Glyceryl monostearate 5g

[0048] PEG60008g

[0049] Montelukast Sodium 10g

[0050] Loratadine 20g

[0051] Measure an appropriate amount of 95% ethanol solution, weigh Eudragil L100 according to the prescription ratio, stir and dissolve, dissolve the pulverized montelukast sodium and loratadine powder in the above solution, add glyceryl monostearate and PEG6000, Spray, feed rate 10ml / min, atomization pressure 0.3Mpa, air inlet temperature 90-130 ℃, air outlet temperature 60-80 ℃, prepare microcapsules containing montelukast sodium and loratadine, including Seal rate>85%.

[0052] The prepared microcapsules containing montelukast sodium and loratadine were directly compressed into tablets according to the following prescription (each tablet) to prepare chewable tablets,

[0053] Montelukast sodium effective dose 5mg

[0054] Loratadine effective dose 10mg

[0055]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a chewable medicine tablet for treating child allergic rhinitis. An effective dose of montelukast sodium and clarityn are made into micro-capsules; the medicine stability is improved; a good odor masking effect is also achieved; and the chewable medicine tablet is suitable for children to take.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to a medicinal chewable tablet for treating allergic rhinitis in children. Background technique [0002] In recent years, the incidence of children with allergic rhinitis has been increasing. 1,200,000 children from 98 countries participated in an international study of asthma and allergic rhinitis. The study found that 8.8%, 13.1%, and 8.3% of children aged 6-7 in North America, South America, and Western Europe suffered from allergic rhinitis. 80% of patients with allergic rhinitis symptoms were diagnosed with allergic rhinitis before the age of 20. Among them, 80-90% of allergic rhinitis will continue into adulthood. Allergic rhinitis usually presents with symptoms such as runny nose, stuffy nose, watery eyes, nasal itching and sleep disturbance. These symptoms can appear all year round and seriously affect the quality of life of children. [0003] The close relati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/47A61K9/20A61P37/08A61P11/02A61K31/4545
Inventor蔡进石利平吉民陈峻青陈国庆尹晓龙龚仕荣徐春涛
OwnerJIANGSU ALPHA PHARM CO LTD